Health Care
Ansell Limited (ANN)
Ansell Limited is a global leader in providing superior health and safety protection solutions that enhance human well-being. The company designs, develops, and manufactures a wide range of protection solutions, primarily surgical, examination, and industrial gloves, as well as protective body suits. Ansell operates globally with a strong presence in both the healthcare and industrial sectors, supported by well-known brands like Gammex, Microflex, and AlphaTec.
Market Cap
A$4.7B
Shares on Issue
N/A
Price Chart
AI Analysis
Ansell's recent performance has been defined by the post-COVID normalisation period, characterised by significant customer de-stocking, falling average selling prices, and the challenge of working through high-cost inventory. This has led to compressed margins and lower revenue compared to the pandemic-era peaks. The company has responded by focusing on rigorous cost control, operational efficiency improvements, and divesting non-core assets to streamline its portfolio and strengthen its balance sheet.
The growth outlook for Ansell is tied to the stabilisation of its end markets and the execution of its strategic priorities. Key catalysts include the end of the de-stocking cycle leading to a resumption of normal ordering patterns, and successful product innovation in higher-margin segments. The company's strategic direction involves investing in manufacturing automation, expanding its presence in emerging markets, and pursuing bolt-on acquisitions that complement its core portfolio in high-growth areas of health and industrial safety.
Bull Case
- • Defensive demand from the healthcare sector, underpinned by aging populations, rising healthcare standards, and the non-discretionary nature of surgical and examination gloves.
- • Strong global market position and brand recognition, which provide a competitive advantage, customer loyalty, and a degree of pricing power.
- • Potential for significant margin recovery as raw material input costs stabilise and benefits from operational efficiency programs are fully realised.
Bear Case
- • High sensitivity to fluctuations in raw material prices, particularly nitrile butadiene rubber (NBR) and natural rubber latex, which can directly impact gross margins.
- • Intense and persistent price competition from low-cost Asian manufacturers, especially in the commoditised single-use examination glove segment.
- • Exposure to global supply chain disruptions, geopolitical risks, and foreign exchange volatility due to its worldwide manufacturing and sales footprint.
Recent Announcements
Becoming a substantial holder
Appointment of Non-executive Director
Notice of FY26 Half Year Results Announcement
Ansell announces CEO to retire, new CEO appointed
🚨 Price SensitiveAnsell Corporation's current CEO is set to retire with the appointment of a new leader. Investors should monitor this transition for potential impact on company performance and strategy direction.
Change in substantial holding
FAQs
What does ANN do?
Ansell is a global manufacturer and marketer of personal protective equipment (PPE), specializing in protective gloves and body protection suits for both the healthcare (surgical and exam gloves) and industrial sectors (chemical and mechanical protection).
Is ANN a good investment?
Ansell can be considered a solid long-term investment due to its market leadership and the defensive nature of its products. However, investors should be aware of short-to-medium term risks including margin pressure from raw material costs, intense competition, and the ongoing normalization of demand after the COVID-19 pandemic.
What drives ANN's share price?
Key drivers include the balance of global supply and demand for protective gloves, raw material prices (like nitrile and latex), global health trends, industrial safety regulations, and the company's ability to manage its manufacturing costs and supply chain effectively.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.